02:33 , Dec 8, 2018 |  BioCentury  |  Product Development

Intermittent move beyond Blincyto

A swath of data at ASH shows that companies have been able to move beyond the 28-day continuous dosing of Amgen Inc.’s first-generation BiTE, Blincyto, to build next-generation antibodies with more convenient, intermittent dosing and...
04:15 , Apr 13, 2018 |  BC Innovations  |  Targets & Mechanisms

Hello RNA

BioCentury’s analysis of new and emerging targets presented at this year’s AACR meeting reveals a surge in activity in non-coding RNAs, as researchers continue to expand target space. The results also reflect the ongoing high...
23:52 , Nov 6, 2017 |  BC Extra  |  Preclinical News

Team identifies new target for MM CAR T therapy

In a paper published in Nature Medicine , researchers at Osaka University and colleagues identified activated integrin beta(7) as a new target for a chimeric antigen receptor (CAR) T cell therapy for multiple myeloma, demonstrating...
21:31 , Dec 2, 2016 |  BioCentury  |  Emerging Company Profile

Passing CARs

CAR T therapies have produced profound responses in hematological cancers, but also severe toxicities such as cytokine release syndrome. Triumvira Immunologics Inc. ’s T Cell-Antigen Coupler platform combines the specificity of chimeric antigen receptors with...
07:00 , Oct 22, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Wilms tumor 1 (WT1); CD3e molecule epsilon (CD3-TCR complex)(CD3ε; CD3E)

Cancer INDICATION: Cancer; leukemia Cell culture and mouse studies suggest a bispecific T cell engager (BiTE) antibody targeting WT1 and CD3ε could help treat cancer and leukemia. The BiTE consisted of ESK1 - which is...
07:00 , Jul 19, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Hematology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Hematology Immunodeficiency CD3e molecule-e CD3-TCR complex (CD3E) Mouse studies suggest anti-CD3E mAbs could help treat Omenn syndrome, a form of severe combined...
08:00 , Feb 24, 2011 |  BC Innovations  |  Distillery Techniques

Technology: Disease models

This week in techniques Approach Summary Licensing status Publication and contact information Disease models Transgenic mouse model of diabetes A new mouse model expressing a human component of the CD3 complex may provide a way...
07:00 , Aug 21, 1995 |  BC Week In Review  |  Clinical News

Protein Design Labs preclinical data

PDLI (Mountain View, Calif.) announced animal evidence that its bispecific antibodies have potential clinical use in preventing micrometastases after cancer therapy. The bispecific antibody directed against the gp52 mouse mammary tumor viral protein, and the...